golotimod and Hepatitis-C--Chronic

golotimod has been researched along with Hepatitis-C--Chronic* in 1 studies

Reviews

1 review(s) available for golotimod and Hepatitis-C--Chronic

Article	Year
SCV-07 (SciClone Pharmaceuticals/Verta). Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:2 SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential treatment of tuberculosis and hepatitis C virus infection. Phase II clinical trials of the compound are ongoing. Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antiviral Agents; Clinical Trials as Topic; Dipeptides; Drug Administration Schedule; Drug Evaluation, Preclinical; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Lassa virus; Mycobacterium tuberculosis; Papillomaviridae; Spleen; Thymus Gland; Tuberculosis	2006

Article

Year

SCV-07 (SciClone Pharmaceuticals/Verta).

Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:2

SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential treatment of tuberculosis and hepatitis C virus infection. Phase II clinical trials of the compound are ongoing.

Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antiviral Agents; Clinical Trials as Topic; Dipeptides; Drug Administration Schedule; Drug Evaluation, Preclinical; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Lassa virus; Mycobacterium tuberculosis; Papillomaviridae; Spleen; Thymus Gland; Tuberculosis

2006